Scientific Reviews
Product Guides
Blogs
Topics
Targeted therapy! The Capetin Prize winning "Click Chemistry" can be used like this!Targeted therapy! The Nobel Prize winning "Click Chemistry" can be used like this!2025-02-06
257 Results for "
payload
" in MedChemExpress (MCE) Product Catalog:
Products (257)
257 Results for "payload" in MCE Product Catalog:
Cat. No.: HY-P991294
Target:
Research Areas:
Cat. No.: HY-P99829
CAS No.: 1869937-48-3
Synonyms: PF-06647020; ABBV-647; h6M24-vc0101
Research Areas:
Research Areas:
PROTAC BRD4 Degrader linker conjugate is a linker-payload conjugate as well as a bifunctional degrader of BRD4 that binds to VHL, consisting of PROTAC and a linker. PROTAC BRD4 Degrader linker conjugate can be conjugated with STEAP1 and CLL1 antibodies to degrade BRD4 protein, with DC50 values of 0.86 nM and 7.6 nM, respectively. PROTAC BRD4 Degrader linker conjugate can be used in research related to prostate cancer and acute myeloid leukemia (BRD4 ligand: (HY-129939); VHL ligand: (HY-125845)) .\n
Cat. No.: HY-170554
Cat. No.: HY-178836
CAS No.: 3077488-78-6
Target:
Research Areas:
Z56-L23 is a conjugate of RAS-targeting ADC cytotoxic payload-linker with anti-tumor activity. Z56-L23 can be conjugated with HER3 antibody, EGFR antibody or EGFRxHER3 bispecific antibody to form intact antibody-drug conjugates (ADCs). ADC molecules related to Z56-L23 effectively inhibit the proliferation of tumor cells and also significantly suppress tumor growth in xenograft mouse models. Z56-L23 can be used in the research of pancreatic cancer .
Cat. No.: HY-185830
Research Areas:
ADC Control Human IgG1-vcMMAE (DAR8) is an antibody-drug conjugate (ADCs), serving as an isotype control for ADC human IgG1-vcMMAE, and inhibits tubulin polymerization. The antibody moiety of ADC Control Human IgG1-vcMMAE (DAR8) is Human IgG1 kappa, Isotype Control (HY-P99001), while the cytotoxic payload and linker moiety are VcMMAE (HY-15575). ADC Control Human IgG1-vcMMAE can be used in cancer-related research .
Cat. No.: HY-189236
CAS No.: 3111620-80-2
Research Areas:
XJ-4-85 is a covalent activator and precursor compound targeting PFKL (EC50=56 μM in human PFKL). XJ-4-85 activates glycolysis, increases FBP production and glycolytic flux, and enhances LPS-stimulated proinflammatory cytokine release in macrophages. XJ-4-85 causes long-chain acylcarnitine accumulation, metabolic stress, and cytotoxicity through the release of the active payload XJ-4-119 targeting CPT2. XJ-4-85 exhibits broad and selective cytotoxicity across multiple cancer cell lines and is useful for melanoma research .
Cat. No.: HY-P9994
CAS No.: 2500674-05-3
Synonyms: SBT6050
Research Areas:
Cat. No.: HY-187336
CAS No.: 3087291-80-0
Nampt-IN-22 is a nicotinamide phosphoribosyltransferase (NAMPT) inhibitor. Nampt-IN-22 blocks the NAD + salvage synthesis pathway by inhibiting nicotinamide phosphoribosyltransferase (NAMPT). Its tertiary alcohol forms hydrogen bonds with His191 of NAMPT and enhances lysosomal stability via intramolecular hydrogen bonds. As an ADC payload, Nampt-IN-22 exhibits low nanomolar cytotoxicity against tumor cells after conjugation to an anti-CD30 antibody, prolongs survival in a disseminated L540 Hodgkin lymphoma mouse model, and suppresses subcutaneous tumor growth. Nampt-IN-22 can be used in studies related to Hodgkin lymphoma .
Cat. No.: HY-P5098
CAS No.: 250612-47-6
Target:
Research Areas:
Cat. No.: HY-181741
Target:
Research Areas:
PI3K-001 is a cathepsin B-responsive prodrug and antifibrotic agent. PI3K-001 undergoes cathepsin B-mediated cleavage of the Val-Ala linker in fibrotic lung lesions to release an active PI3K inhibitor payload, while it remains stable in healthy tissues. PI3K-001 improves collagen deposition, tissue collapse and alveolar injury in fibrotic lung tissues. PI3K-001 is applicable for the research of pulmonary fibrosis .
Cat. No.: HY-P990673
Synonyms: DSTP-3086S Antibody; RG-7450 Antibody
Research Areas:
Cat. No.: HY-171689
CAS No.: 2760250-80-2
Synonyms: AZD 8205; P-Sam
Research Areas:
Puxitatug samrotecan (AZD 8205) is an antibody-drug conjugate (ADC) targeting B7-H4, formed by the random conjugation of the Puxitatug (HY-P990059) antibody and AZ14170133 (HY-145399) via interchain cysteine reduction. Puxitatug samrotecan binds to B7-H4 to deliver the payload to B7-H4-expressing cells, inhibits topoisomerase I, and induces cytotoxicity in cancer cells and xenograft models. Puxitatug samrotecan can be used in studies of B7-H4-expressing tumors .
0 Images
Sgc8c-M
Cat. No.: HY-177571
Synonyms: Sgc8c-VcMMAE
Cat. No.: HY-180557
Target:
Research Areas:
4A-BFA-11 is a folate-targeted PEG-MMAE conjugate that exhibits specific binding affinity for the folate receptor α (FR-α) (KD = 106.7 nM). 4A-BFA-11 achieves tumor enrichment by combining PEG-mediated long circulation (EPR effect) and folate receptor targeting. 4A-BFA-11 undergoes enzymatic cleavage at the tumor site to release the active payload, enabling precise action. 4A-BFA-11 sefficiently carries, targets, and controls the release of MMAE in tumor tissues in a HeLa mouse model. 4A-BFA-11 can be used for cervical cancer, ovarian cancer, and lung cancer research .
Cat. No.: HY-P992356
Target:
Research Areas:
Cat. No.: HY-12455
CAS No.: 118292-34-5
Research Areas:
Duocarmycin A is an antitumor antibiotic and DNA alkylating agent with broad-spectrum antibacterial activity, which can serve as a payload for synthesizing antibody-drug conjugates (ADCs). Duocarmycin A selectively binds to the AT-rich minor groove of DNA, forms covalent adducts by alkylating the adenine N3 residue, thereby disrupting DNA structure and inhibiting its replication and transcription. Duocarmycin A induces apoptosis, sub-G1 phase accumulation and chromatin condensation, reduces the levels of pro-caspase-3/9, and induces p53-independent p21 expression. Duocarmycin A is widely used in the research of various malignancies, including leukemia, sarcoma, glioblastoma, as well as multiple solid tumor models such as lung cancer, breast cancer, and colorectal cancer .
Research Areas:
PSMA-Val-Cit-PAB-MMAE is a small-molecule conjugate targeting PSMA, with Monomethyl auristatin E (MMAE) (HY-15162) as its cytotoxic payload. PSMA-Val-Cit-PAB-MMAE binds to PSMA, thereby being delivered into PSMA-expressing prostate cancer cells. Subsequently, the Val-Cit linker is cleaved under the mediation of cathepsin B, releasing active MMAE. PSMA-Val-Cit-PAB-MMAE inhibits CYP3A4 activity (IC50 = 11.2 μM), induces intracellular ROS production and oxidative stress, disrupts the cytoskeleton through microtubule destabilization, and induces prostate cancer cell death. PSMA-Val-Cit-PAB-MMAE can be used in research related to prostate cancer .
Research Areas:
MC-GGFG-AM-(10Me-11F-Camptothecin) is a linker-payload conjugate used to synthesize ZW251. ZW251 an antibody-drug conjugate (ADC) targeting human GPC3. ZW251 consists of a humanized IgG1 antibody conjugated to a novel camptothecin-based topoisomerase 1 inhibitor, ZD06519, via a linker. The linker is the maleimide anchor and a glycyl glycyl phenylalanyl glycine (GGFG)-aminomethyl (AM) cleavable linker. ZW251 has high affinity with human and cynomolgus monkey GPC3. ZW251 displays rapid internalization in GPC3-expressing HCC cell lines, and bystander-mediated killing of GPC3 negative cancer cells .
Cat. No.: HY-177542
CAS No.: 2855974-40-0
Synonyms: Emi-Le; XMT-1660
Research Areas:
Emiltatug ledadotin (Emi-Le; XMT-1660) is a B7-H4-targeted antibody-drug conjugate (ADC). Emiltatug ledadotin consists of the tumor-specific anti-B7-H4 monoclonal antibody Emiltatug (HY-P990918) and the linker-payload system Ledadotin (HY-177541), with site-specific conjugation achieved via GlycoConnect click chemistry. Emiltatug ledadotin inhibits the growth of B7-H4-positive cancer cells. Emiltatug ledadotin can be used to study advanced solid tumors with B7-H4 overexpression, particularly breast cancer, ovarian cancer, and endometrial cancer .
-
-
Protocols
Targeted therapy! The Capetin Prize winning "Click Chemistry" can be used like this!Targeted therapy! The Nobel Prize winning "Click Chemistry" can be used like this!A suitable model is crucial in drug screening experiments. Organs can mimic the three-dimensional functional structure of internal organs, have similar spatial organization to corresponding organs, maintain some key characteristics, and reproduce some physiological functions. They are widely used for modeling and personalized drug screening physiological functions.2025-02-06
